Gurrea-Rubio, Mikel
Wu, Qi
Amin, M. Asif
Tsou, Pei-Suen
Campbell, Phillip L.
Amarista, Camila I.
Ikari, Yuzo
Brodie, William D.
Mattichak, Megan N.
Muraoka, Sei
Randon, Peggy M.
Lind, Matthew E.
Ruth, Jeffrey H.
Mao-Draayer, Yang
Ding, Shengli
Shen, Xiling
Cooney, Laura A.
Lin, Feng
Fox, David A.
Funding for this research was provided by:
NIH Autoimmunity Center of Excellence (T32AR007080)
Frederick Huetwell and William Robinson Professorship in Rheumatology at the University of Michigan
Michigan Translational Research And Commercialization program from the University of Michigan
Article History
Received: 2 October 2023
Accepted: 10 December 2023
First Online: 27 January 2024
Declarations
:
: Drs. Fox and Lin hold equity in Abcon, a company created to test the use of therapeutic agents that interrupt the interactions between CD6 and CD6 ligands.
: This study was approved by the University of Michigan Institutional Review Board.
: Written informed consent was received from participants prior to inclusion in the study.